Samsung Biologics posts massive revenue growth as labor union rally sets strike in motion
As Samsung Biologics presented a massive quarterly revenue growth, 2,200 people rallied ahead of a planned labor union strike.
Medical News
Merck goes with Google for AI push, striking enterprise partnership worth up to $1B
Amid industry layoffs and M&A headlines, Big Pharma's embrace of AI is gaining more steam.
Hidden virus in your gut may be linked to colon cancer
A newly discovered virus hiding inside a common gut bacterium could help explain one of medicine’s long-standing mysteries: why a microbe found in both healthy people and cancer patients is linked to colorectal cancer. The research suggests that the interaction between bacteria and the viruses they carry may be key to understanding disease risk. It may even lead to future screening tests that dete
A simple blood test could reveal Alzheimer’s risk years early
A routine blood marker tied to inflammation may reveal Alzheimer’s risk years in advance. Scientists found that higher neutrophil levels—part of the body’s first immune response—were linked to a greater chance of developing dementia. The discovery suggests this common lab value could help flag at-risk individuals before symptoms appear. It also raises the possibility that immune cells themselves m
Novartis launches ‘Sjöut for Sjögren’s campaign, teams with Carrie Ann Inaba
Novartis is running a new disease awareness campaign for Sjögren's syndrome with help from dancer, choreographer, and TV personality Carrie Ann Inaba.
Two common drugs may reverse fatty liver disease, study finds
Scientists have discovered that combining two existing drugs can dramatically reduce liver fat linked to a common and often silent disease. The treatment not only improved liver health in animal models but also showed potential to lower heart-related risks. Interestingly, using lower doses of both drugs together worked just as well as higher doses alone. While promising, the findings still need to
STAT+: With successful trials, Roche takes its MS drug to regulators, but safety questions loom
The Swiss drugmaker Roche presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek approval.
STAT+: From Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it
A company that is changing the outlook on pancreatic cancer has more promising data for treatments near-term and for a generation beyond.
STAT+: Kyverna Therapeutics plans to submit cell therapy for stiff person syndrome for FDA approval
A one-time cell therapy from Kyverna Therapeutics for stiff person syndrome, a rare disease, improved mobility and reduced disabilities in a late-stage trial.
Flu vaccine no longer mandated for U.S. troops, defense secretary says
Defense Secretary Pete Hegseth announced Tuesday that the U.S. military will no longer require all American troops to get the flu vaccine.
STAT+: UnitedHealth earnings beat expectations in the first quarter, but hurdles persist
UnitedHealth’s financial performance in the first quarter far exceeded analyst’s expectations in both its Optum and UnitedHealthcare divisions.
STAT+: RFK Jr. to face four GOP doctors at Senate hearings
We'll be zeroed in on Kennedy's exchanges with one doc in particular: Bill Cassidy.
Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso
The once-daily HIV treatment regimen offers a new mechanism of action in the HIV treatment market.
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
Pfizer's chief strategy and innovation officer Andrew Baum is stepping down merely two years into the role, according to reports.
The Oral GLP-1 Tracker: Following the launch trajectories of Lilly’s Foundayo, Novo’s Wegovy pill
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts’ notes and IQVIA data to monitor prescription trends and shifting market shares as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie to become the go-to oral weight-loss solution for millions.
AstraZeneca eyes 5th Ultomiris indication after kidney disease trial win
In a phase 3 trial in the rare kidney disease IgAN, AstraZeneca said its Ultomiris delivered a clinically meaningful and statistically significant reduction in protein from the urine after 34 weeks.
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect Welireg surprisingly failed to ignite hope as a first-line treatment.
Scientists discover hidden “master switch” driving skin cancer growth and immune escape
A key protein, HOXD13, helps melanoma tumors grow and evade the immune system by boosting blood supply and blocking cancer-fighting T cells. Disabling it shrinks tumors and reopens the door for the immune system—offering a new path for treatment.
Scientists discover skincare compound that kills drug-resistant bacteria
A popular Korean skincare ingredient may be far more powerful than anyone realized. Scientists have discovered that madecassic acid—derived from the herb Centella asiatica—can stop antibiotic-resistant bacteria in their tracks, including dangerous strains of E. coli. By targeting a bacterial protein that humans don’t have, the compound disrupts the microbes’ ability to survive, making it a promisi
STAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem
At AACR, a bold use of CAR-T raises hopes and provocative questions about its use in smoldering multiple myeloma.